Article

Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric Cancer/GEJ Cancer

04/19/2022

– Promising efficacy seen including in patients with PD-L1 low tumors – Favorable safety profile with minimal additive safety burden in combination – Updated results of the ongoing study presented in oral presentation at American Association for Cancer Research (AACR) Annual Meeting Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., April 12, 2022 /PRNewswire/ — Trishula Therapeutics, Inc., a…

Read More

Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia

04/19/2022

New Research from Trinity College Dublin Indicates Broader Therapeutic Potential for ART27.13 Excerpt from the Press Release: SOLANA BEACH, Calif., April 13, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that ART27.13, a peripherally selective…

Read More

Agilent Highlights Genomics and Cell Analysis Solutions for Cancer Research at AACR 2022

04/18/2022

Excerpt from the Press Release: Agilent Technologies Inc. (NYSE: A) today announced cancer research innovations in cell analysis and genomics that will be on show at the American Association for Cancer Research Annual Meeting, being held April 8 – 13, 2022 in New Orleans, Louisiana. “Cancer research is an important focus area for Agilent. The AACR…

Read More

T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting

04/18/2022

Excerpt from the Press Release: SAN FRANCISCO, April 08, 2022 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced it is advancing its second TCR-T program, TK-2504, toward the clinic and presented preclinical data on its ability to generate novel TCRs targeting the KRASG12V antigen. The…

Read More

Boundless Bio Presents Data on the Novel Discovery of the Association Between Extrachromosomal DNA (ecDNA) and Replication Stress at the American Association for Cancer Research Annual Meeting 2022

04/18/2022

The study reveals replication stress in ecDNA enabled cancers as a unique vulnerability and therapeutic strategy for treating gene amplified cancers Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today will present a new finding at the American…

Read More

MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

04/15/2022

Excerpt from the Press Release: LA JOLLA, Calif., April 07, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a secondary analysis of a Phase 2 clinical trial of MN-166 (ibudilast) in alcohol…

Read More

Akston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine

04/15/2022

1,500 healthy volunteers to participate in a Phase II/III double-blind placebo-controlled study in India Study results to be submitted for Emergency Use Authorization (EUA) Vaccine is shelf stable for over six months at room temperature at 25° Celsius (77° Fahrenheit) and maintains potency for one month at 37° Celsius (99° Fahrenheit) Excerpt from the Press…

Read More

Advaxis Announces Publication of ADXS-PSA Data in The Oncologist

04/15/2022

ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with visceral metastasis Median overall survival of 16.4 months for patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to ~9 months from historical data with KEYTRUDA® alone Median overall survival of 33.7…

Read More

Carevive Systems and Blue Spark Technologies Partner to Conduct Real-Time Remote Patient Monitoring Pilot

04/14/2022

Pilot aims to prevent symptoms in advance with contextualized data for cancer patient care Excerpt from the Press Release: (Carevive), the leading oncology-focused health technology company centered on understanding and improving the cancer patient experience, announced today a partnership with Blue Spark Technologies, a leader and an innovator in wearable wireless medical device solution The study…

Read More

Proof Diagnostics Submits Request For Emergency Use Authorization Seeking First Approval Of Crispr-based Molecular Point-of-care Covid-19 Test

04/14/2022

If authorized by the FDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for COVID-19 (SARS-CoV-2) in as little as 18 minutes Excerpt from the Press Release: CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ — Proof Diagnostics, Inc., an innovative healthcare technology company delivering innovative solutions in molecular diagnostics, today announced the submission…

Read More